Table 1 Frequency and duration of dashboard interactions in the 43 participating general practices in Salford during the first year of the SMASH intervention. All presented data are medians (interquartile range) across practices
| Â | Median average number of views per month (IQR) | Median average time spent in minutes per month (IQR) | Median total number of at-risk patients (IQR) |
|---|---|---|---|
Users | |||
 Any user | 6.6 (4.2–9.3) | 113.8 (74.1–183.2) |  |
 Pharmacists | 5.9 (3.3–8.2) | 104.7 (51.2–136.0) |  |
 Practice staff | 0.5 (0.0–1.5) | 5.3 (0.0–27.6) |  |
Time | |||
 First quarter | 12.0 (5.0–15.2) | 217.4 (108.4–319.6) |  |
 Second quarter | 4.5 (2.8–7.4) | 69.6 (37.7–102.8) |  |
 Third quarter | 6.3 (3.7–10.2) | 90.4 (50.0–172.2) |  |
 Fourth quarter | 5.7 (2.7–9.3) | 88.4 (27.4–155.9) |  |
Dashboard pages | |||
 Practice summary | 9.1 (5.3–14.2) | 181.5 (66.9–289.0) |  |
 Table overview | 18.4 (12.2–28.9) | 765.9 (380.6–1132.9) |  |
 Chart overview | 0.9 (0.4–3.0) | 25.2 (4.6–119.2) |  |
 Indicator information | 0.5 (0.2–1.0) | 67.0 (4.5–228.8) |  |
 Patient list (any medication safety indicator) | 19.3 (14.1–35.6) | 2907 (1722.0–5371.3) | 67 (45–128.5) |
Patient lists for specific types of medication safety risks | |||
1. Prescription of an oral NSAID without co-prescription of an ulcer-healing drug in a patient aged ≥65 years | 4.4 (2.5–9.0) | 747.9 (338.9–1307.8) | 26 (11.5–42.5) |
2. Prescription of an oral NSAID without co-prescription of an ulcer-healing drug to a patient with a history of peptic ulceration | 0.3 (0.1–1.0) | 13.1 (0.4–92.2) | 1 (1–3) |
3. Prescription of an antiplatelet drug without co-prescription of an ulcer-healing drug to a patient with a history of peptic ulceration | 2.0 (0.5–2.8) | 224.4 (98.1–456.4) | 4 (2–6.5) |
4. Prescription of warfarin or NOAC in combination with an oral NSAID | 1.3 (0.5–1.9) | 98.7 (39.3–211.7) | 4 (2–6) |
5. Prescription of warfarin or NOAC in combination with an antiplatelet drug without co-prescription of an ulcer-healing drug | 1.3 (0.8–2.5) | 130.3 (77.5–358.2) | 4 (2–9) |
6. Prescription of an aspirin in combination with another antiplatelet drug without co-prescription of an ulcer-healing drug | 2.5 (1.1–3.8) | 345.5 (142.6–532.6) | 8 (5–13) |
7. Prescription of a non-selective beta-blocker to a patient with asthma | 3.8 (2.0–5.5) | 600.3 (358.0–914.2) | 15 (8–28.5) |
8. Prescription of a long-acting beta-2 inhaler (excluding combination products with inhaled corticosteroid) to a patient with asthma who is not also prescribed an inhaled corticosteroid | 0.8 (0.0–1.7) | 65.2 (0.0–188.6) | 2 (0–6) |
9. Prescription of an oral NSAID to a patient with heart failure | 0.8 (0.3–1.8) | 50.9 (5.5–123.0) | 2 (1–5) |
10. Prescription of an oral NSAID to a patient with chronic renal failure (eGFR< 45) | 0.5 (0.2–1.3) | 55.7 (0.8–114.8) | 3 (1.5–5) |
11. Prescription of methotrexate without both a recent full blood count and a recent liver function test | 1.2 (0.7–2.3) | 158.2 (70.3–315.1) | 4 (2.5–6) |
12. Prescription of amiodarone without a thyroid function test | 1.5 (0.8–3.3) | 191.7 (40.3–358.3) | 4 (2–6) |
Multiple medication safety indicators | 0.3 (0.1–0.7) | 17.5 (0.8–158.0) | 4 (2–7) |